Supportive cancer therapy encompasses a wide variety of clinical problems and interventions that confront the patient and provider. The study of each of these areas requires expertise in the biology and pathophysiology of the process, as well as an understanding of the therapeutic approaches to management, which have become progressively more sophisticated from a pharmacologic and multidisciplinary perspective. In this issue of Supportive Cancer Therapy, there are important updates on neutropenia, mucositis, anemia, catheter-related thrombosis, management of tumor lysis syndrome, medical and surgical approaches to pain management, and new antiemetic agents. In addition, the area of supportive care issues in older patients with cancer is reviewed, as well as access to palliative radiation therapy. This range of topics is a wonderful demonstration of the breadth of this field and also of the broad knowledge base needed for all of us as we try to provide the best cancer care possible.
In the area of neutropenia, one of the Meeting Highlights from the 2004 Annual Meeting of the American Society of Hematology (ASH), held in San Diego in December, describes the incidence of neutropenic events during chemotherapy in patients with cancer. The reported study is an ongoing prospective community registry that documents the high prevalence of neutropenia and febrile neutropenia with standard chemotherapy regimens. This large prospective database will lead to a risk model to identify those patients most likely to experience neutropenia and febrile neutropenia. Then, future studies will be asked to evaluate proactive interventions rather than current reactive strategy.
Other Meeting Highlights review a number of interesting topics presented at ASH. In studies by Trifilio and colleagues, it is clear that a single low dose of rasburicase, a recombinant form of urate oxidase, along with allopurinol and hydration, is effective in preventing hyperuricemia associated with tumor lysis syndrome in adult patients with hematologic malignancies. The initial approval of this agent was for pediatric patients, so it is gratifying to see the benefit of this agent extended to adult patients as well.
Another major topic at ASH was the study of cancer-and cancer treatment-related anemia and its management with erythropoietic agents. One report describes a potential interaction of erythropoietin use and risk of thromboembolic events in patients with rectal and gastric cancer receiving chemoradiation therapy. This relatively small study was interrupted because of a high rate of thromboembolic events in this population. The potential interaction of erythropoiet-ic agents and thrombotic risk was reviewed at a meeting of the Oncologic Drugs Advisory Committee (ODAC) last spring and was reported in a previous issue of Supportive Cancer Therapy. The results of metaanalyses of the erythropoietic agents, as confirmed in the initial approval of these agents, demonstrated an increase in thrombotic risk in patients with cancer receiving erythropoietic agents. What complicates this area is the already elevated risk for thrombosis that patients with cancer have based on the disease and therapy. Although it is not entirely clear, the risk of these events may be higher in patients whose hemoglobin levels are greater than the target of 12-13 g/dL. Clearly, further studies are needed in this area, particularly to help us understand what mechanisms may be operative and whether prophylactic interventions would be effective. Meanwhile, it is reassuring that, in other ASH presentations, metaanalyses of epoetin and darbepoetin from the same ODAC meeting demonstrated no negative effect on survival outcome in patients with cancer when the agents were used according to treatment guidelines for the anemic patient.
Another meeting highlight reviewed from ASH was the incidence of symptomatic catheter-related thrombosis in patients with cancer. This article demonstrates that the actual catheter-related thrombosis is lower in the hands of these investigators than had been previously expected. Although many practitioners have used low-dose warfarin as prophylaxis, these authors suggest that intervention may not be necessary.
One of the Research in Brief articles discusses the role of palifermin in reducing oral mucositis induced by intensive cancer therapy. This review of the pivotal trial by Spielberger and colleagues, published in the New England Journal of Medicine, documents the clinical benefit of recombinant human keratinocyte growth factor in a randomized placebo-controlled trial of patients with hematologic malignancies undergoing high-dose chemotherapy and total body irradiation before bone marrow transplantation. This trial documents a clinically important reduction in incidence and duration of mucositis in the palifermin group, as well as improvement in important patient outcomes such as mouth soreness and swallowing. Palifermin will provide important clinical benefits to patients undergoing high-dose chemotherapy. Studies of palifermin in other settings of chemotherapy-and radiation therapy-related mucositis are ongoing. After years of research in mucositis with relatively little progress in terms of therapeutic intervention, this is truly an exciting time with the arrival of palifermin in the clinical arena and the potential that agents like fibroblast growth factor (FGF)-20 may also provide in the future.
The second Research in Brief article describes a potential approach to managing fever using prophylactic levofloxacin in patients with solid tumors or lymphoma. In this metaanalysis of 9 studies presented at the 2004 Annual Meeting of the European Society of Medical Oncology, the use of levofloxacin compared with placebo led to significant reduction of fever, probable infection, and hospitalization in this population. Because of the concern regarding drug-resistant bacterial pathogens, guidelines groups have not yet endorsed this policy routinely, but clearly this is an area of further study. Another approach, covered by Morrison in a Comprehensive Review, uses antibiotics and antifungal agents to treat febrile neutropenia. This provides the reader with the evolution of our treatments with antibiotics and, in particular, the nuances of antifungal treatment for patients with prolonged neutropenia. These articles will hopefully help the practitioner better understand the epidemiology of neutropenia, ongoing studies for preventive strategies, and appropriate interventions in the treatment of patients with febrile neutropenia.
The issue of pain management is also addressed in a comprehensive review by Wu and Fourney. One evolving area of pain management in patients with cancer has been the incorporation of vertebroplasty in patients with back pain caused by osteolytic metastases. This minimally invasive procedure involves subcutaneous injection of a polymethylmethacrylate bone cement into a fractured vertebral body. The pain relief may be a result of the stabilization of microfractures or restoration of vertebral body strength. Regardless of the theory, it is clear from the article that this approach, which can be a useful adjunct to other standard approaches, can lead to significant pain relief for patients with cancer who have compression fractures and can also be associated with significant improvement in function.
The first Original Contribution discusses the barriers to accessing care that may occur in times of crisis. Lee and colleagues studied the impact of the severe acute respiratory syndrome (SARS) epidemic on access and utilization of palliative radiation therapy. It was clear that, during the SARS epidemic, there was a reduction in palliative radiation therapy services resulting from the overall impact of the SARS epidemic on medical services. The authors suggest that use of single-fraction therapy and delayed follow-up visits may help to minimize hospital transfers and visits if there are future infectious disease outbreaks.
The second Original Contribution looks at the area of antiemetic agents. Mandanas and colleagues have performed a randomized multicenter open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for prevention of nausea and vomiting during high-dose myeloablative chemotherapy followed by stem cell support for patients with breast cancer or lymphoma. Both agents were well tolerated and equally safe and effective in this setting, in which 46%-47% of patients experienced total and complete response. Thus, this study demonstrates that both these agents are appropriate options in management. It also points out that there is clearly room for the addition of new agents and directions to achieve better overall control of nausea and emesis in patients receiving these high-dose regimens.
Finally, in an article on Translational Medicine, Alvarez and colleagues discuss a preclinical model of oral mucositis enhanced and treated with 5-fluorouracil, radiation, and the activity of recombinant human FGF-20. This novel agent was effective in significantly reducing the duration of severe oral mucositis. It also had beneficial effects when given on a multiday schedule in animals with established mucositis. Clinical trials with this agent are eagerly awaited.
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